Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B

Value in Health

Volumn 13, Issue 8, 2010, Pages 922-933

  Dakin, Helen ^a,b   Bentley, Anthony ^a   Dusheiko, Geoff ^c  

^a Decision Resources Group   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

cost utility analysis; hepatitis B virus infection; lamivudine; net benefit approach; nucleoside; nucleotide; tenofovir; Viread

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS B; HUMAN; LIVER DISEASE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 78650083042     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00782.x     Document Type: Article

References (73)

1. Hepatitis B Foundation UK. Rising curve: chronic hepatitis B infection in the UK. 2007. Available from: [Accessed June 17, 2010.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
3. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
4. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23.
5. British Medical Association. British National Formulary (BNF), No. 54. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2007.
6. Roche Products Limited. Summary of product characteristics for Pegasys 180 microgram pre-filled syringe. 2009.
7. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
8. Colonno RJ, Rose RE, Pokornowski K, et al. Four year assessment of entecavir resistance in nucleoside naïve and lamivudine refractory patients. Podium presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain. 2007.
9. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
10. Snow-Lampart A, Sorbel J, Chappell B, et al. Lack of tenofovir DF (TDF) resistance mutations in treatment naïve and treatment-experienced subjects with chronic HBV infection following 48 weeks of TDF mono-therapy. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, April 23-27, 2008, Milan, Italy. 2008.
11. Dakin H, Fidler C, Niziol C,. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of chronic hepatitis B. Value Health 2010; 13:In press.
12. Bristol-Myers Squibb Pharmaceuticals Ltd. Entecavir (BaracludeÂ) for the treatment of chronic hepatitis B: single technology appraisal submission to the National Institute for Health & Clinical Excellence. November 2007. Available from: [Accessed July 22, 2010.
13. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
14. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
15. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-92.
16. Van Bommel F, Mauss S, Schurmann D, et al. No evidence for tenofovir resistance in patients with lamivudine-resistant HBV infection during long-term treatment for up to 5 years. Hepatology 2006; 44 (suppl. 1): A549.
17. Van Bommel F, De Man R, Erhardt A, et al. First multicenter evaluation of the efficacy of tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfection. Hepatology 2007; 46: 270A.
18. Berg T, Moeller B, Trinh H, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV). Podium presentation #1219 at the 2008 European Association for the Study of the Liver conference. 2008.
19. Dore G, Cooper D, Pozniak AL, et al. Anti-hepatitis B virus (HBV) activity in HBV/HIV co-infected patients treated with tenofovir DF (TDF) and lamivudine (LAM) versus LAM alone: 144-week follow-up. 15th International AIDS conference. 2004: Abstract 3308.
20. Gilead Sciences Ltd. DATA ON FILE-TDF001: Patient Years Exposure to Tenofovir Disoproxil Fumarate (TDF) (All Products). 2008.
21. Snow-Lampart A, Chappell B, Curtis M, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomised to receive tenofovir DF 300 mg QD. Poster presentation at AASLD 2008. 2008.
22. Zethraeus N, Johannesson M, Jonsson B, et al. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics 2003; 21: 39-48.
23. Stinnett AA, Mullahy J,. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18: S68-80.
24. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. Second edition. 2008. Available from: [Accessed June 15, 2010.
25. Gilead Sciences. Tenofovir (VireadÂ) for the treatment of chronic hepatitis B. Single technology appraisal manufacturer submission to the National Institute for Health and Clinical Excellence. December 2008. Available from: [Accessed June 17, 2010.
26. Government Actuary's Department. Interim life tables: expectation of life based on data for years 2005-2007. Available from: [Accessed June 17, 2010.
27. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
28. Gilead Sciences. Summary of product characteristics for Hepsera 10 mg tablets. 2007. Available from: [Accessed July 22, 2010.
29. Gilead Sciences. Summary of product characteristics for Viread 300 mg tablets. 2008. Available from: [Accessed July 22, 2010.
30. Bristol-Myers Squibb. Summary of product characteristics for Baraclude 0.5 mg film and 1.0 mg film coated tablets. 2007. Available from: [Accessed July 22, 2010.
31. GlaxoSmithKline UK. Summary of product characteristics for Zeffix 100 mg film-coated tablets. 2007. Available from: [Accessed July 22, 2010.
32. Crowley SJ, Tognarini D, Desmond PV, et al. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17: 409-27.
33. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 153: entecavir for the treatment of chronic hepatitis B. August 2008. Available from: [Accessed June 17, 2010.
34. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 173. Tenofovir disoproxil for the treatment of chronic hepatitis B. July 2009. Available from: [Accessed June 17, 2010.
35. National Institute for Health and Clinical Excellence. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B. Technology Appraisal Guidance No 96. London, February 2006.
36. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 154: telbivudine for the treatment of chronic hepatitis B. August 2008. Available from: [Accessed June 17, 2010.
37. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. June 2008. Available from: [Accessed June 17, 2010.
38. De Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39 (Suppl. 1): S3-25. (Pubitemid 37222643)
39. Crowley S, Tognarini D, Desmond P, et al. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002; 17: 153-64.
40. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-8.
41. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-6.
42. Sung JJY, Lai JY, Zeuzem S, et al. A randomised double-blind phase II study on lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naive patients with chronic hepatitis B: week 52 analysis [Abstract]. J Hepatol 2003; 38: 25-6.
43. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36. (Pubitemid 41096641)
44. Heathcote J, George J, Gordon S, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, April 23-27, 2008, Milan, Italy. 2008.
45. FDA. Baraclude prescribing information. 2007. Available from: [Accessed August 2, 2008.
46. Borroto-Esoda K, MIller MD, Reiser H,. Clinical virology report review and approval: adefovir dipivoxil integrated resistance summary. Fourth Edition: May 18, 2006. 2006.
47. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-60.
48. Marzano A, Gaia S, Barbon V, et al. Therapy with adefovir alone or combined with lamivudine in patients with lamivudine-resistant chronic hepatitis B: clinical and virological aspects. Hepatology 2006; 44: 231a.
49. Tziomalos K, Vassiliadis T, Giouleme O, et al. Adefovir dipivoxil plus lamivudine combination treatment is superior to adefovir dipivoxil monotherapy in lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B patients. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, November 2-6, 2007. 2007: Abstract No. 956.
50. Lampertico P, Viganò M, Iavarone M, et al. Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years. Podium presentation at the 41st Annual Meeting of the European Association for the Study of the Liver 2006. 2006; Abstract No. 989.
51. Lampertico P, Viganò M, Manenti E, et al. Five years of sequential LAM to LAM + ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma. J Hepatol 2006; 44 (Suppl. S2): S38.
52. Pellicelli A, Barbaro G, Francavilla R, et al. Clinical covariates associated with virological response and adefovir resistance in chronic hepatitis B HbeAg negative lamivudine-resistant patients treated with adefovir alone or in combination with lamivudine for 28 months. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, November 2-6, 2007. 2007.
53. Longworth L, Young T, Ratcliffe J, et al. Economic evaluation of the Transplantation Programme in England and Wales: An assessment of the costs of liver transplantation. Unpublished Report to the Department of Health. 2001.
54. Longworth L, Young T, Buxton MJ, et al. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transpl 2003; 9: 1295-307.
55. Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006; 10: 1-113. iii.
56. Curtis L, Netten A,. Unit Costs of Health and Social Care 2007. Canterbury, UK: PSSRU Personal Social Services Research Unit, 2007.
57. Shepherd J, Jones J, Takeda A, et al. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10:iii-iv, xi-xiv, 1-183.
58. Ossa D, Briggs AH, Tafesse E, et al. Impact on quality of life of health states induced by chronic hepatitis B infection: estimates from uninfected and infected persons in the UK. Poster presentation at the International Society for Pharmacoeconomics & Outcomes Research (ISPOR) 8th Annual European Congress, Florence, Italy, November 6-8. 2005.
59. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008; 11: 527-38.
60. Kind P, Hardman G, Macran S,. UK Population Norms for EQ-5D. York: Centre for Health Economics, 1999.
61. Wong JB, Koff RS, Tine F, et al. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-75.
62. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22: 290-308.
63. Briggs AH,. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479-500.
64. Kamal A, Gerson L, Ahmed A,. Cost-effectiveness of new treatment paradigms for e-Ag negative chronic hepatitis B. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, November 2-6, 2007. 2007: Abstract No. 987.
65. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142: 821-31. (Pubitemid 40664041)
66. Monthly Index of Medical Specialities (MIMS). London: Haymarket Medical Publications Ltd, June 2008.
67. Gilead Sciences. Study GS-US-174-0102: a randomized, double-blind, controlled evaluation of tenofovir DF versus adefovir dipivoxil for the treatment of presumed pre-core mutant hepatitis B. Clinical study report, Gilead Sciences, data on file. 2007.
68. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, November 2-6. 2007: Abstract No. LB2.
69. Gilead Sciences. Study GS-US-174-0103. A randomised, double-blind, controlled evaluation of tenofovir DF versus adefovir dipivoxil for the treatment of HBeAg positive chronic hepatitis B. Clinical study report, Gilead Sciences, data on file. 2007.
70. Heathcote E, Gane E, DeMan R, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, November 2-6, 2007. 2007: Abstract No. LB6.
71. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
72. Foundation for Liver Research. Hepatitis B: Out of the shadows. 2004. Available from: [Accessed July 22, 2010.
73. McGuire A,. Chapter 1: theoretical concepts in the economic evaluation of health care. In:, Drummond M, McGuire A, eds. Economic Evaluation in Health Care-Merging Theory with Practice. Oxford, New York: Oxford University Press, 2001.